Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.72|
|52 Week High||US$2.42|
|52 Week Low||US$5.22|
|1 Month Change||-5.23%|
|3 Month Change||-20.93%|
|1 Year Change||-24.44%|
|3 Year Change||-55.26%|
|5 Year Change||n/a|
|Change since IPO||-72.25%|
Recent News & Updates
Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Mustang Bio remains underfollowed despite having several therapies that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases. MBIO's share price is near the 52-week lows despite the company completing milestones and a few bullish catalysts ahead. Several programs are moving closer to their pivotal studies. I review some of the recent updates and discuss how they bolster my bullish outlook. In addition, I point out some of my leading downside risks. I take a look at charts to map out my next MBIO buy.
|MBIO||US Biotechs||US Market|
Return vs Industry: MBIO underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: MBIO underperformed the US Market which returned 30.7% over the past year.
Stable Share Price: MBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MBIO's weekly volatility (6%) has been stable over the past year.
About the Company
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
Is Mustang Bio undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MBIO ($2.73) is trading below our estimate of fair value ($14.01)
Significantly Below Fair Value: MBIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MBIO is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.1x).
How is Mustang Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MBIO is forecast to have no revenue next year.
High Growth Revenue: MBIO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBIO's Return on Equity is forecast to be high in 3 years time
How has Mustang Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MBIO is currently unprofitable.
Growing Profit Margin: MBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MBIO is unprofitable, and losses have increased over the past 5 years at a rate of 31.6% per year.
Accelerating Growth: Unable to compare MBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: MBIO has a negative Return on Equity (-46.57%), as it is currently unprofitable.
How is Mustang Bio's financial position?
Financial Position Analysis
Short Term Liabilities: MBIO's short term assets ($131.3M) exceed its short term liabilities ($6.4M).
Long Term Liabilities: MBIO's short term assets ($131.3M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: MBIO is debt free.
Reducing Debt: MBIO currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MBIO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 39.6% each year.
What is Mustang Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Manny Litchman (67 yo)
Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio Inc. since April 24, 2017. Dr. Litchman served as the Chief Executive Officer and...
CEO Compensation Analysis
Compensation vs Market: Manny's total compensation ($USD1.17M) is about average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Manny's compensation has increased whilst the company is unprofitable.
Experienced Management: MBIO's management team is considered experienced (3.1 years average tenure).
Experienced Board: MBIO's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MBIO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.7%.
Mustang Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Mustang Bio, Inc.
- Ticker: MBIO
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$247.850m
- Shares outstanding: 91.12m
- Website: https://www.mustangbio.com
Number of Employees
- Mustang Bio, Inc.
- 377 Plantation Street
- 1st floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:52|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.